Search results for "ulcerative colitis."

OP29 Tofacitinib in ulcerative colitis: Real-world evidence from Eneida Registry

2020

Abstract Background Our aim was to evaluate the effectiveness and safety of tofacitinib in ulcerative colitis (UC) in real life. Methods Patients from the prospectively maintained ENEIDA registry treated with tofacitinib due to active UC were included. Clinical activity and effectiveness were defined based on Partial Mayo Score (PMS). The short-term response was assessed at week 4, 8 and 16. The last-observation-carried-forward method was used in patients that stopped tofacitinib before the time-points for clinical assessment. Variables associated with short-term remission at week 8 were identified by logistic regression analysis. The cumulative retention rate and the cumulative incidence o…

Peptidergic Innervation in Chronic Pancreatitis

1990

The reason for the generation and continuation of chronic pain in chronic pancreatitis is unclear [6, 10, 11, 13, 61, 117]. Current concepts of the neurobiology of pain point to the possible role of various neuropeptides in pain processing and inflammation [8, 29, 32, 33, 44, 60, 64, 65, 68, 79, 104, 112]. A key function has been ascribed to the proinflammatory and pronociceptive peptides of the tachykininin (TK) family (8, 44, 104, 109]. That the tachykinin substance P (SP) may be involved in chronic inflammatory and painful disease of the gastrointestinal system is evidenced by a selective increase in the density of tachykinin receptors in the bowels of patients suffering from Crohn’s dis…

P658 The Inflammatory Bowel Disease Disability Index (IBD-DI) in ulcerative colitis is related to disease activity, need of immunosuppressive therapy…

2017

Multifocal Pyoderma Gangrenosum Resistant to Infliximab in Active Ulcerative Colitis: Donʼt Forget the Role of Cyclosporin

2012

Cytomegalovirus disappearance after treatment for refractory ulcerative colitis in 2 patients treated with infliximab and 1 patient with leukapheresis

2009

Use of Calprest ® in the diagnosis of Inflammatory Bowel Disease (IBD)

2002

Abstract Background: Between November 2000 and February 2001 a study has been performed by eight Italian hospital centers with the aim of verifying the usefulness of Calprest® (detection of fecal calprotectin) as a marker of bowel inflammation. Preliminary data are reported. Objective: To define the use of fecal calprotectin as a marker of intestinal inflammation, to assess whether it might help in differentiating between IBS and IBD, and its role in IBD. Subjects: Healthy population (51), active Crohn (16), non active or under remission Crohn (11), active ulcerative Colitis (8), non active or under remission ulcerative Colitis (13), pathological Controls of various nature (79). Results: Th…

P611 Outcome in ulcerative colitis after switch from subcutaneous anti-TNF to intravenous anti-TNF: A multicentre study

2018

Chromoendoscopy: An Evolving Standard in Surveillance for Ulcerative Colitis

2004

Ulcerative colitis - How can we improve surveillance colonoscopy?

2003

Therapeutic Potential of the Gabaergic System in Ulcerative Colitis: Current Status and Perspectives

2017

This concise commentary deals with the manuscript, in the issue 10, volume 32 of Digestive Diseases and Sciences 2017, by Aggarwal et al. which provides data supporting the contribution of GABA and GABAergic signalling to the pathogenesis of ulcerative colitis (UC) in humans